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SUMMARY – Angiogenesis is essential for the development, growth and progression of tumors. 
Although vascular endothelial growth factor (VEGF) is a well-known proangiogenic factor, its impact 
on lymphoma has not yet been fully clarifi ed. Th e aim of this study was to evaluate VEGF-A  expression 
and microvessel density (MVD) in aggressive lymphoma such as diff use large B-cell lymphoma 
(DLBCL), in indolent lymphomas such as low-grade follicular lymphoma (FL), and in lymph node 
reactive follicular hyperplasia (FH). In 80 prospective and retrospective cases (30 DLBCL, 30 FL and 
20 FH), CD31 was analyzed by immunohistochemical staining assessing density of blood vessels, as 
well as the total number of CD31 positive endothelial cells. Th e results were compared with relevant 
clinical data. MVD was 85% in FH, followed by 60% in DLBCL and 43% in low-grade FL. VEGF-A 
was signifi cantly higher in DLBCL than in low-grade FL and FH. A statistically signifi cant associa-
tion of MVD and VEGF-A with the International Prognostic Index (IPI) was found in DLBCL. 
High MVD and VEGF-A expression was observed in DLBCL patients with high IPI, while there 
was no statistically signifi cant association between MVD and VEGF-A with the Follicular Lym-
phoma International Prognostic Index in low-grade FL. Our results suggested an important relation-
ship between angiogenesis and high-grade lymphoma.
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Introduction
Diff use large B-cell lymphoma not otherwise spec-
ifi ed (DLBCL) is the most common type of lymphoid 
tumor worldwide1,2, and displays striking heterogene-
ity at clinical, genetic, and molecular levels. DLBCL 
was included both in the Revised European American 
Lymphoma (REAL) and World Health Organization 
(WHO) classifi cations aiming to describe all malig-
nant lymphomas characterized by the large size of 
neoplastic cells, B-cell derivation, aggressive clinical 
presentation, and need for highly eff ective chemother-
apy regimens3,4.
Follicular lymphoma (FL) is the second most com-
mon non-Hodgkin’s lymphoma. Th is disease aff ects 
lymph nodes, and 50% of patients present with bone 
marrow infi ltration. However, the mechanisms in-
volved in dissemination of the disease are still unclear5. 
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FL is divided into three grades. Grades 1 and 2 are 
considered as lymphoma of low-grade malignancy6. 
Angiogenesis is the formation of new capillaries by 
outgrowth of endothelial cells from preexisting blood 
vessels7.
Th e Vascular Endothelial Growth Factor/Vascu-
lar Endothelial Growth Factor Receptor (VEGF/
VEGFR) pathway is a key mediator of angiogene-
sis  and VEGF-A acts as a potent tumor angiogenic 
factor. VEGF-A stimulates the growth of new blood 
vessels that provide tumors with oxygen and nutrients, 
which in turn determine the proliferative activity of 
the tumor. Expression of VEGF-A has been shown to 
be regulated at the transcriptional and translational 
levels8,9.
VEGF-A mediated angiogenesis has received con-
siderable attention in the context of solid neoplasia, 
particularly with the clinical use of anti-VEGF-A an-
tibodies and small molecule VEGFR inhibitors. More 
recently, the concept of tumor vascularity has been ap-
plied to hematolymphoid neoplasia, with studies 
quantifying microvessel density (MVD) in a variety of 
lymphomas10,11.
VEGF-A-mediated signaling has at least two po-
tential roles in DLBCL, i.e. potentiation of angiogen-
esis, and potentiation of lymphoma cell proliferation 
and/or survival induced by autocrine VEGFR-medi-
ated signaling10-12.
Given the rapidly increasing availability of a variety 
of pharmaceuticals aimed at the VEGF-A pathway, 
the role of angiogenesis and VEGF-A signaling in 
DLBCL may be of great interest10.
In non-Hodgkin’s lymphomas, expression of an-
giogenic factors in cell lines14 and neoplastic tissue15-17 
has been demonstrated. Although these studies sug-
gest a role for angiogenesis in lymphomas, several 
questions remain unanswered. In addition, determina-
tion of MVD as a measure of the degree of angiogen-
esis is also one of the most examined parameters for 
angiogenesis in cancers13. It is not clear whether high 
MVD is associated with more aggressive lymphomas.
Th e aim of this study was to evaluate VEGF-A ex-
pression and MVD through expression of CD31 in 
endothelial cells in aggressive lymphomas such as 
DLBCL, in indolent lymphomas such as FL, and in 
lymph node reactive follicular hyperplasia (FH).
Furthermore, we analyzed the correlation of 
VEGF-A expression and MVD with the Internation-
al Prognostic Index (IPI) in patients with DLBCL 
and Follicular Lymphoma International Prognostic 
Index (FLIPI) in patients with low-grade FL.
Materials and Methods
In our study, we evaluated VEGF-A and CD31 ex-
pression in 30 DLBCL, 30 FL and 20 FH cases diag-
nosed at the Institutes of Pathology, Faculty of Medi-
cine, University of Prishtina and Faculty of Medicine, 
St. Cyril and Methodius University in Skopje.
Immunohistochemistry
Th e slides were deparaffi  nized and rehydrated us-
ing standard procedures. Microwave heating was used 
for antigen retrieval and slides were then IHC stained 
using VEGF-A (A-20, 1:150 dilution; Santa Cruz 
Biotechnology Inc., USA, and CD31 (Clone JC70A, 
RTU; DAKO, Denmark) antibodies.
Protein expression of VEGF-A observed mainly in 
the cytoplasm of tumor cells was scored by combining 
the quantity score (percentage of positive stained cells) 
with the staining intensity score. All slides were ana-
lyzed independently by three pathologists. Th e quan-
tity score ranged from 0 to 4: 0 = no immunoreactivity; 
1 = <25% cells stained; 2 = 26%-50% cells stained; 3 = 
51%-75% cells stained; and 4 = >76% cells stained. 
Th en, scores 1-4 were clustered into two groups: group 
I (scores 1 and 2) and group II (scores 3 and 4). Th e 
staining intensity was scored as: 0 (negative), 1 (weak 
positivity, seen at X400 magnifi cation), 2 (moderate, 
seen at X100 magnifi cation), and 3 (strong, seen at 
X40 magnifi cation). Th e fi nal score was obtained by 
multiplying the groups of quantity score and intensity, 
as follows: 0 = no immunoreactivity; 1 = low positivity 
(1%-50% of cells stained and seen at X400); 2 = mod-
erate positivity (1%-50% cells stained and seen at 
X40x or >50% of cells stained and seen at X400); and 
3 = high positivity (51%-100% cells stained and seen 
at X40).
Microvessel counting was used for angiogenesis as-
sessment. CD31 immunostained tumor sections were 
scanned at low power magnifi cation (X100) to identify 
the areas with highest vascular density, so called ‘hot-
spots’; then MVD was calculated as the mean value of 
CD31-positive cells and cell clusters in fi ve hot spots 
per section evaluated at X200 magnifi cation. Subse-
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quently, the MVD median value was used to classify 
each group of tumors in ‘high’ and ‘low’ MVD, by three 
independent observers to obtain consensus of catego-
rization. Th e cut-off  to categorize ‘low’ and ‘high’ 
MVD was a mean value of 10 blood vessels.
Prognostic index
Th e scoring systems, known as the IPI for DLBCL 
and FLIPI for FL, were used to compare results with 
clinical data. Th ree risk groups were categorized using 
the IPI and FLIPI scoring system: low risk, intermedi-
ate risk, and high risk18,19.
Statistical analysis
Univariate analysis was performed to assess the 
percentage distribution and other main characteristics 
of single variables used in testing the hypotheses. Th e 
χ2-test was used to test diff erences and bivariate analy-
sis to test correlation between categorical variables. All 
hypotheses were tested at the 0.05 level of signifi cance.
Results
Expression of VEGF-A in DLBCL was scored as 
follows: no immunoreactivity, 1 (3%) case; low positiv-
ity, 5 (17%) cases; moderate positivity 17 (57%) cases; 
and high positivity, 7 (23%) cases (Fig. 1). However, in 
FL, VEGF-A expression was scored as follows: no im-
munoreactivity, 5 (17%) cases; low positivity, 4 (13%) 
cases; moderate positivity, 19 (63%) cases; and high 
positivity, 2 cases (7%). Lastly, in FH, 5 (25%) cases 
showed low positivity and 15 (50%) cases showed 
moderate positivity, while no cases showed high posi-
tivity (Table 1).
Positive staining for CD31 was detectable in the 
membrane of endothelial cells in the stroma. Of 30 
DLBCL cases, 18 (60%) showed high MVD and 12 
(40%) showed low MVD, whereas in FL 13 (43%) 
cases showed high MVD and 17 (57%) cases showed 
low MVD. Control group (FH) was found to have a 
very high expression of MVD, as 16 (80%) cases 
showed high MVD and only 4 (20%) cases showed 
low MVD (Fig. 2). Th e p-values obtained by the χ2-
test yielded statistically signifi cant diff erences between 
the two groups of MVD (χ2=6.688, df=2, p=0.035) 
(Table 2).
Expression of VEGF-A was compared for the re-
lationship with clinical data, i.e. prognostic index (IPI 
for DLBCL and FLIPI for FL). One DLBCL case 
without staining also had low IPI, 5 of 7 cases with 
high VEGF-A immunoreactivity had high IPI, an-
Table 1. Number of cases per group and expression 
of vascular endothelial growth factor-A
VEGF-A
Score ranges
0 1 2 3
DLBCL 1 5 17 7
Low-grade FL 5 4 19 2
FH 5 5 10 0
VEGF-A = vascular endothelial growth factor-A; DLBCL = dif-
fuse large B-cell lymphoma; FL = follicular lymphoma; FH = fol-
licular hyperplasia
Fig. 1. VEGF-A expression: (A) no immunoreactivity; 
and (B) high immunoreactivity at X40 magnifi cation.







χ2=6.688, DF=2, p-value 0.035
MVD = microvessel density; DLBCL = diff use large B-cell lym-
phoma; FL = follicular lymphoma; FH = follicular hyperplasia
Fig. 2. CD31 staining: (A) low microvessel density; 
and (B) high microvessel density at X40 magnifi cation.
A AB B
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other 2 cases had intermediate IPI, and no case with 
high immunoreactivity had high IPI (Table 3). How-
ever, 4 out of 5 FL cases with no VEGF-A immuno-
reactivity showed low FLIPI, and 1 case had interme-
diate FLIPI. Of 2 FL cases with high expression of 
VEGF-A, 1 case had high and intermedicate FLIPI 
each.
Expression of MVD was also compared for the re-
lationship with clinical data, i.e. prognostic index (IPI 
for DLBCL and FLIPI for FL). Out of 17 cases of FL 
with low MVD, 8 showed low, 5 intermediate and 4 
high FLIPI. Four of 13 cases with high MVD showed 
low FLIPI, 7 intermediate FLIPI, and only 2 showed 
high FLIPI. Based on the test performed, there were 
no statistically signifi cant diff erences between MVD 
and FLIPI (χ2=1.833, df=2, p=0.4).
In DLBCL, diff erent results were noted. Eight of 
12 cases with low MVD showed low IPI, 3 cases inter-
mediate, and only 1 case high IPI. No case with high 
MVD was in the category of low IPI, however, 13 
cases were in the intermediate and 5 in the high IPI 
category. Study results showed highly statistically sig-
nifi cant correlation between MVD and IPI in DLB-
CL (χ2=16.372, df=2, p-=0.000, Spearman correla-
tion=0.633) (Table 4).
Discussion
Angiogenesis is a multistep process playing a cru-
cial role in the progression and metastasis of various 
tumors, including those of visceral organs and hema-
tolymphoid malignancies20. Tumor angiogenesis has 
been well documented both in experimental and clini-
cal studies, and the degree of angiogenesis was closely 
associated with tumor progression and shorter patient 
survival in many types of cancer21,22. Non-Hodgkin’s 
lymphomas are a diverse group of lymphoproliferative 
neoplasms with a variable clinical behavior and prog-
nosis. Currently, lymphomas are classifi ed on the basis 
of morphology, immunology, genetic, and clinical fea-
tures. Th e clinical stage of the lymphoma is the most 
important prognostic factor, apart from the histologic 
grade (indolent versus aggressive)20.
Microvessel density measures lymphoma neovas-
cularity generated in response to tumor cells, proan-
giogenic stromal cells, and infi ltrating benign T/B 
lymphocytes and myeloid cells within the tumor mi-
croenvironment. Th erefore, MVDs vary greatly among 
diff erent studies due to the heterogeneity of lympho-
ma stroma, the range of cell surface markers used for 
staining, and diff erences in scoring methodology. Th e 
clinical predictive value of MVD with respect to un-
derlying lymphoma subtypes remains unclear23.
In general, MVD scores trend highest in aggressive 
subtypes of lymphoma, compared with lower ones in 
indolent lymphoma. Gratzinger et al. report that aver-
age MVDs did correlate with the intensity of VEGF 
staining in a statistically signifi cant manner24. In an-
other study, increasing MVD was found to be a poor 
prognostic indicator for overall but not progression-
free survival, and was independent of the IPI25,.
Koster et al.11 found that in FL, high MVD as a 
variable of increased tumor vascularization was associ-
ated with a signifi cantly more favorable outcome in 
terms of both progression-free and overall survival26. 
Positive association between MVD and patient out-
come is in contrast with the notion that in hemato-
logic malignancies, as well as in solid tumors the in-
crease of angiogenesis-associated variables is related to 
adverse prognosis15,22,28. Aggarwal et al.20 found higher 
MVD in aggressive lymphoma such as peripheral T-
Table 4. Correlation between International Prognostic 
Index in DLBCL and VEGF-A
IPI
VEGF-A Low Intermediate High
0 1 0 0
1 4 1 0
2 4 12 3
3 0 2 5
DLBCL = diff use large B-cell lymphoma; IPI = International 
Prognostic Index; VEGF-A = vascular endothelial growth factor-
A; study results showed highly statistically signifi cant correlation 
between VEGF-A and IPI in DLBCL
Table 3. Correlation between International Prognostic 
Index in DLBCL and expression of CD31
Variable IPI









χ2=16.372, DF=2, p-value 0.000, Spearman correlation=0.633
DLBCL = diff use large B-cell lymphoma; IPI = International 
Prognostic Index
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cell lymphoma and DLBCL, and low MVD in low-
grade lymphomas2.
In our study, VEGF-A and CD31 staining were 
evaluated as markers of tumor vascularity in lymph 
nodes, showing signifi cant diff erence in terms of 
MVD between high-grade lymphoma (DLBCL), 
which demonstrated high MVD, and low-grade FL, 
which showed low MVD.
Ganjo et al.29,30 report that antiangiogenic drugs 
have modest clinical activity in lymphomas as a single 
agent. Our results may suggest that antiangiogenic 
therapy could be active only in high-grade lymphomas 
expressing stronger VEGF.
Conclusion
Neoangiogenesis has been increasingly recognized 
to play potentially important pathogenic roles in lym-
phomagenesis. We can conclude that our results sup-
port the hypothesis that there is important relation-
ship between angiogenesis and high-grade lymphoma. 
Also, there is signifi cant correlation with clinical data.
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Sažetak
KLINIČKA VAŽNOST VEGF-A I MIKROŽILNE GUSTOĆE 
U DIFUZNOM LIMFOMU VELIKIH B-STANICA I FOLIKULARNOM LIMFOMU NISKOG STUPNJA
L. Shahini, S. Gašparov, G. Petruševska, S. Manxhuka Kerliu, F. Veselaj, F. Kurshumliu i F. Kavaja
Angiogeneza je bitna za razvoj, rast i progresiju tumora. Iako je vaskularni endotelni faktor rasta (VEGF) dobro poznati 
proangiogeni čimbenik, njegov utjecaj na limform nije u potpunosti razjašnjen. Cilj ovoga istraživanja bio je procijeniti izra-
ženost VEGF-A i mikrožilnu gustoću (MVD) kod agresivnog limfoma kao što je difuzni limfom velikih B-stanica (DLBCL), 
kod indolentnih limfoma kao što je folikularni limfom niskog stupnja (FL) i kod reaktivne folikularne hiperplazije limfnih 
čvorova (FH). Analiza CD31 provedena je u 80 prospektivnih i retrospektivnih slučajeva (30 DLBCL, 30 FL i 20 FH) 
imunohistokemijskim bojenjem za procjenu gustoće krvnih žila, kao i ukupnog broja endotelnih stanica pozitivnih na CD31. 
Rezultati su uspoređeni s relevantnim kliničkim podacima. MVD je bila 85% kod FH, 60% kod DLBCL i 43% kod FL 
niskog stupnja. VEGF-A je bio značajno viši u DLBCL u odnosu na FL niskog stupnja i FH. Statistički značajna udruže-
nost MVD i VEGF-A s Internacionalnim prognostičkim indeksom (IPI) utvrđena je kod DLBCL. Visoka izraženost MVD 
i VEGF-A zabilježena je u bolesnika s DLBCL s visokim IPI, dok nije bilo statistički značajne udruženosti MVD i 
VEGF-A s Internacionalnim prognostičkim indeksom za folikularni limfom kod FL niskog stupnja. Rezultati ovog istraži-
vanja ukazuju na važan odnos između angiogeneze i limfoma visokog stupnja.
Ključne riječi: Vaskularni endotel, faktor rasta A; Limfom, ne-Hodgkin; Limfom velikih B-stanica, difuzni; Limfom, folikular-
ni; Limfni čvorovi; Hiperplazija
